<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248117</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4929s</org_study_id>
    <nct_id>NCT01248117</nct_id>
  </id_info>
  <brief_title>Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy</brief_title>
  <acronym>PEARL2</acronym>
  <official_title>Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab (2.0mg) Prospectively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Consultants of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Consultants of Hawaii</source>
  <brief_summary>
    <textblock>
      Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal
      choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved
      anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed with spectral oct, 4m BCVA, ICG, FA and monthly eye examinations
      for one year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of intravitreal injections of 2.0mg ranibizumab administered monthly in preventing vision loss</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the efficacy of intravitreal injections of 2.0mg ranibizumab administered monthly in preventing vision loss, as measured by calculating the mean change in VA from baseline to Month 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of intravitreal injections of 2.0mg ranibizumab administered monthly</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the safety and tolerability of intravitreal injections of 2.0mg ranibizumab administered monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of monthly intravitreal injections of 2.0mg ranibizumab in preventing vision loss</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the efficacy of monthly intravitreal injections of 2.0mg ranibizumab in preventing vision loss as measured by the following: mean change from baseline in VA at 6 and 12 months, and the proportion of subjects who lose less than 5 letters of vision at Month 6 and Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the efficacy of monthly intravitreal injections of 2.0mg ranibizumab on clinical findings associated with PCV</measure>
    <time_frame>1 year</time_frame>
    <description>the mean change from baseline at M6 to M12 of subretinal hemorrhage and/or exudates via fundus photographs and fundus exams, decrease and/or complete resolution of branching vascular network from PCV at M3, M6, and M12 as assessed by FA and ICG, decrease and/or complete resolution of the branching vascular network (BVN) from PCV at M3, M6, and M12, as assessed by FA and ICG, mean change in central foveal thickness and/or peripapillary edema as measured by SD-OCT in central and/or paracentral fields from baseline, M3, M6 and M12, incidence of ocular AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Previously Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-Naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-Naive: no previous treatment for PCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 2.0mg</intervention_name>
    <description>Monthly, intravitreal injection 0.05ml</description>
    <arm_group_label>Previously Treated</arm_group_label>
    <arm_group_label>Treatment-Naive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt;= 25 years

          -  Polypoidal choroidal vasculopathy as noted on fluorescein and ICG angiography: active
             leakage, active bleeding or recent decrease in vision

          -  BVCA using ETDRS of 20/32 to 20/400

        Exclusion Criteria:

          -  Any history of prior vitrectomy

          -  Any prior treatment with verteporfin PDT in the study eye

          -  Previous cataract surgery within the preceding 2 months of D0

          -  Active intraocular inflammation in the study eye

          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
             eye

          -  A condition, that in the opinion of the investigator, would preclude participation in
             the study (e.g. unstable medical status including blood pressure, cardiovascular
             disease)

          -  Participation in another investigational trial within 30 days of randomization that
             involved treatment with any drug that has not received regulatory approval at the time
             of study entry.

          -  Prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days prior to
             enrollment in this study

          -  Known allergy to any component in the study drug

          -  Uncontrolled hypertension: &gt;180/110

          -  major surgery within 28 days prior to randomization

          -  Myocardial infarction, other cardia events requiring hospitalization within 6 months
             prior to randomization

          -  Systemic anti-VEGF or pro-VEGF within 3 months of randomization

          -  Pregnancy or lactation

          -  History of recurrent significant infections or bacterial infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg T Kokame, MD, MMM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants of Hawaii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline F Shen</last_name>
    <phone>(808) 380-8060</phone>
    <email>jshen@retinahi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii</name>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline F Shen</last_name>
      <phone>808-380-8060</phone>
      <email>jshen@retinahi.com</email>
    </contact>
    <investigator>
      <last_name>Gregg T Kokame, MD, MMM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James C Lai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Wee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii, Inc</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline F Shen</last_name>
      <phone>808-380-8060</phone>
      <email>jshen@retinahi.com</email>
    </contact>
    <investigator>
      <last_name>Gregg T Kokame, MD, MMM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James C Lai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Wee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>November 24, 2010</last_update_submitted>
  <last_update_submitted_qc>November 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gregg T. Kokame / Managing Partner</name_title>
    <organization>Retina Consultants of Hawaii</organization>
  </responsible_party>
  <keyword>PCV</keyword>
  <keyword>polypoidal</keyword>
  <keyword>choroidal</keyword>
  <keyword>vasculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

